Skip to main navigation

Contact Us
Global
- International
- Canada
- France
- Germany
- Italy
- Japan
- Netherlands
- Spain

About Amicus
- About Amicus
- Chairman’s Welcome
- Leadership
- Belief Statement
- Contact Us
- Message from BIO
Patient Advocacy
- Patient Advocacy
- Disease Information
- Rare Stories
- Patient Advisory Boards
- Corporate Giving
- Resources
- Expanded Access
Programs & Pipeline
- Programs & Pipeline
- Our Pipeline
- Fabry Disease
- Pompe Disease
- Batten Disease
- Additional Preclinical Programs
- Clinical Trials
- Platform Technologies
- Journal Articles
- Publications & Posters
Product
- Product
- Galafold^®
- Amicus Assist™
Responsibility
- Responsibility
- Ethics & Compliance
- Global Medical Affairs
- Corporate Giving
- Healing Beyond Disease
- ESG Report
Investors & Media
- Investors & Media
- Investor Relations
- Senior Management Team
- Board of Directors
- Corporate Governance
- Press Releases
- Events & Presentations
- Annual Reports and Proxies
- SEC Filings
- Stock Performance
- Investor FAQs
- Contact Us
- Sign Up for Email Alerts
- Featured Coverage
- Electronic Press Kit
Careers
- Careers
- Overview
- Search

Investors

Press Releases

Press Releases

Year

September 20, 2021

Amicus Therapeutics Announces Presentations at the 26th International Annual Congress of the World Muscle Society

September 3, 2021

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2021

August 5, 2021

Amicus Therapeutics Announces Second Quarter 2021 Financial Results and Corporate Updates

August 4, 2021

Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference

August 2, 2021

Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease

July 27, 2021

Amicus Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021

June 14, 2021

Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of Directors

June 8, 2021

Amicus Therapeutics Announces United Kingdom’s MHRA Grants Early Access to AT-GAA

May 28, 2021

Amicus Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

May 21, 2021

Amicus Therapeutics Announces Upcoming Presentations at the 16th International Congress on Neuromuscular Diseases

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

About Amicus

Patient Advocacy

Programs & Pipeline

Product
- Overview
- Amicus Assist™

Responsibility

Investors & Media

Careers
- Overview
- Search

Social Media
- Twitter
- YouTube
- LinkedIn

Copyright © 2021 Amicus Therapeutics. All rights reserved. NP-AT-ALL-00011119

Cookies Statement
Terms of Use
Privacy Notice
Privacy Shield Policy

The site you are about to enter is intended for US healthcare professionals.

Please confirm you are a US healthcare professional.

I am a US healthcare professional I am not a US healthcare professional